We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bioinformatics Tool for Evaluating the Evaluation of Cancer Genes

By LabMedica International staff writers
Posted on 28 Dec 2016
Researchers offer a new software tool being developed to help assess computational algorithms used in methods to identify mutant genes that drive cancer. More...
The tool could thereby lead to more precise diagnostics and targeted treatments for patients.

In the search for new ways to tackle cancer, many scientists use genome sequencing to hunt for mutations that facilitate tumor cell growth. To aid in this search, some researchers have developed new bioinformatics methods that each claim to help pinpoint the cancer driver mutants. But a question remains: Among the numerous new tactics, which produce more accurate results?

To help solve this puzzle, a team of Johns Hopkins University (Baltimore, MD, USA) computational scientists and cancer experts devised the new tool to help assess how well current strategies work in identifying cancer-promoting mutations and distinguishing them from benign mutations in cancer cells.

"Identifying the genes that cause cancer when altered is often challenging, but is critical for directing research along the most fruitful course," said co-author Bert Vogelstein, Johns Hopkins Kimmel Cancer Center, "This paper establishes novel ways to judge the techniques used to identify true cancer-causing genes and should considerably facilitate advances in this field in the future."

Lead author Collin J. Tokheim, doctoral student in the laboratory of senior author Rachel Karchin, associate professor at Johns Hopkins, said one of the challenges the team faced was the lack of a widely accepted consensus on what qualifies as a cancer driver gene. "People have lists of what they consider to be cancer driver genes, but there's no official reference guide, no gold standard," said Tokheim. Nevertheless, the team was able to develop a machine-learning-based method for driver gene prediction and a framework for evaluating and comparing other prediction methods.

For the study, this evaluation tool was applied to 8 existing cancer driver gene prediction methods. The results were not very reassuring. “These methods still need to get better. We're sharing our methodology publicly, and it should help others to improve their systems for identifying cancer driver genes," said Tokheim.

The study, by Tokheim CJ et al, was published December 13, 2016, in the journal Proceedings of the National Academy of Sciences.

Related Links:
Johns Hopkins University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.